多灶肝细胞癌异质性的多组学研究与临床意义  

Clinical significance of heterogeneity in multifocal hepatocellular carcinoma:A multi-omics study

作　　者：匡铭[1] 许丽霞[2] 刘信 章颖 沈顺利[1] KUANG Ming;XU Lixia;LIU Xin;ZHANG Ying;SHEN Shunli(Department of Liver Surgery,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China;Department of Oncology,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China;Department of Radiotherapy,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院肝外科,广州510080 [2]中山大学附属第一医院肿瘤科,广州510080 [3]中山大学附属第一医院放射治疗科,广州510080

出　　处：《临床肝胆病杂志》2020年第10期2184-2187,共4页Journal of Clinical Hepatology

基　　金：国家自然科学基金资助项目(81825013,81771958)。

摘　　要：超过一半的肝细胞癌(HCC)患者在就诊时肝内已出现多发病灶,临床上针对多灶HCC的治疗手段十分有限且疗效不佳。多灶HCC中肿瘤的高度异质性是导致治疗失败的重要原因。越来越多的研究采用多组学测序,探索多灶HCC中不同病灶间的基因水平和转录水平的异质性,包括肿瘤克隆进化以及基因突变、拷贝数变异、结构变异、RNA表达、肿瘤免疫微环境特征等的异质性。肿瘤克隆进化导致的药物靶点分布以及免疫微环境的特征可精准预测多灶HCC患者对靶向药物和免疫治疗的疗效。因此,全面、准确地评估多灶HCC的多组学异质性对实施精准治疗至关重要。More than half of patients with hepatocellular carcinoma(HCC)have multiple lesions in the liver at the time when they attend the hospital,and there are limited treatment methods with poor efficacy for multifocal HCC in clinical practice.The high degree of tumor heterogeneity in multifocal HCC is the leading cause of treatment failure.More and more studies use multi-omics sequencing to explore the heterogeneity between different lesions at the genetic and transcriptional levels,including tumor clonal evolution,gene mutations,copy number variations,structural variations,RNA expression,and tumor immune microenvironment.Drug target distribution shaped by clonal evolution and the characteristics of immune microenvironment can accurately predict the response to targeted drugs and immunotherapy in patients with multifocal HCC.Therefore,a comprehensive and accurate assessment of the heterogeneity of multifocal HCC based on a multi-omics study is of vital importance in the implementation of precise treatment.

关 键 词：癌 肝细胞 基因 诊断 治疗学 

分 类 号：R735.7[医药卫生—肿瘤]